Open AccessAlteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions
Author(s) -
Sivakumar Sudhakaran,
Teodoro Bottiglieri,
Kristen M. Tecson,
Aaron Y. Kluger,
Peter A. McCullough
Publication year - 2019
Publication title -
reviews in cardiovascular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.555
H-Index - 39
eISSN - 2153-8174
pISSN - 1530-6550
DOI - 10.31083/j.rcm.2018.03.908
Subject(s) - medicine , hyperlipidemia , kidney disease , lipid metabolism , disease , kidney , intensive care medicine , bioinformatics , endocrinology , diabetes mellitus , biology
The role of anti-hyperlipidemic therapy remains of key importance in the treatment of atherosclerotic disease. Moreover, given an already exaggerated predisposition for vascular disease at baseline, there is a preponderance of data that show management of hyperlipidemia is especially important in patients with chronic kidney disease. This is a concise, up-to-date review of lipid physiology, alterations in lipid concentrations with progressive renal failure, and currently available and emerging hyperlipidemic treatment options. Specifically, the roles of these therapies in patients with chronic kidney disease are reviewed.